Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Язвенный колит

Список литературы

  1. Travis S, Dinesen L. Remission intrials of ulcerative colitis: what does it mean? Pract Gastroenterology. 2010;30:17–20.
  2. D"Haens G, Sandborn W, Feagan B et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.
  3. Truelove S, Witts L. et al. Cortisone in ulcerative colitis; final report on a therapeutic trial Br Med J. 1955; 2:1041-1048.
  4. Dignass A, Eliakim R, Magro F et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohns Colitis. 2012 Dec;6(10):965-90. doi: 10.1016/j.crohns.2012.09.003
  5. Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.
  6. Molodecky N, Soon I, Rabi D et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.
  7. De Groof E, Rossen N, Van Rhijn B et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a populationbased cohort in the Netherlands. Eur. J. Gastroenterol Hepatol. 2016;28:1065–72.
  8. Qiu Y, Wen Ren W, Liu Y et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine. 2020;27:100544. doi: 10.1016/j.eclinm.2020.100544
  9. Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463
  10. Burisch J, Pedersen N, Čuković-Čavka S et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014;63(4):588-97.
  11. Katsanos KН, Vermeire S, Christodoulou DК et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007;75: 113–21.
  12. Silverberg M, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.
  13. Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb;43(4):482-513.
  14. Hindryckx P, Jairath V, D"Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):654-664.
  15. Ачкасов С.И., Шапина М.В., Веселов В.В., Варданян А.В., Мингазов А.Ф., Пономаренко А.А. Предикторы колэктомии у пациентов со свертяжелым язвенным колитом. Колопроктология. 2020;19(3):37-48. https://doi.org/10.33878/2073-7556-2020-19-3-37-48
  16. Chen J, Andrews J, Kariyawasam V et al. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul;44(2):127-44.
  17. Schroeder KН, Tremaine W, Ilstrup DМ. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.
  18. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011; № 15, с. 44-49.
  19. Sands B. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126:1518–32.
  20. Perler B, Ungaro R, Baird G, Malette M et al. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inceptive cohort. BMC Gastroenterol. 2019;19:47.
  21. Fine K, Schiller L. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464–86.
  22. Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035–43.
  23. Mahid SS, Minor KS, Soto RE et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–71.
  24. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:2–10.
  25. Mogan G. R. et al. Toxic megacolon in ulcerative colitis complicated by pneumomediastinum: report of two cases //Gastroenterology. – 1980. – Т. 79. – №. 3. – С. 559-562.
  26. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 Jun 1;11(6):649-670. doi: 10.1093/ecco-jcc/jjx008. Erratum in: J Crohns Colitis. 2022 Aug 16;: PMID: 28158501.
  27. Travis SP, Jewell DP. Ulcerative colitis: clinical presentation and diagnosis. In: Satsangi J, Sutherland LR, editors. Inflammatory Bowel Diseases. London: Churchill Livingstone. 2003:169–81.
  28. Lucendo AJ, Arias Á, Roncero Ó, Hervías D, et al. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Sao Paulo Med J. 2014;132(3):140-6.
  29. Irwin JR, Ferguson E, Simms LA, Hanigan K et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn"s Disease. Dig Dis Sci. 2019 Feb;64(2):503-517.
  30. Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflamm Bowel Dis. 2015 Aug;21(8):1769-75.
  31. Feng JR, Qiu X, Wang F, Chen PF, et al. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn"s Disease. Gastroenterol Res Pract. 2017. doi: 10.1155/2017/3526460
  32. Yoon JY, Park SJ, Hong SP, Kim TI, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr;59(4):829-37.
  33. Yamamoto-Furusho JK, Sánchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010 Oct-Dec;9(4):397-401.
  34. Archampong EQ, Harris J, Clark CG. The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro. Gut. 1972 Nov;13(11):880-6.
  35. Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, et al. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis. 2008 Aug;9(3):140-3.
  36. Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Göttl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):418-422.
  37. Axelrad JE1, Joelson A, Green PHR, Lawlor G et al. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct;113(10):1530-1539. doi: 10.1038/s41395-018-0211-8
  38. Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:345-351.
  39. Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
  40. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1432-42.
  41. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443-50.
  42. Kim JJ, Simpson N, Klipfel N, Debose R, et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr;55(4):1059-65. doi: 10.1007/s10620-010-1126-4
  43. Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis.Digestion. 2017;96(3):142-148. doi: 10.1159/000479865.
  44. Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748
  45. Bansal J, Jenaw RK, Rao J et al. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012 Apr;19(2):115-9. doi: 10.1007/s10140-011-1007-y.
  46. Annese V, DapernoM, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2013;7(12):982-1018.
  47. Tanaka M, Saito H, Fukuda S, Sasaki Y et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol. 2000 Mar;35(3):281-6.
  48. Parente F, Greco S, Molteni M et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003;18:1009-1016.
  49. Baltarowich O. H., Scoutt L. M., Hamper U. M. Nongynecologic findings on pelvic ultrasound: focus on gastrointestinal diseases //Ultrasound Quarterly. – 2012. – Т. 28. – №. 2. – С. 65-85.
  50. Smith R., Taylor K, Friedman AB et al. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis. 2020 May 21;14(4):465-479. doi: 10.1093/ecco-jcc/jjz163
  51. Kılıçkesmez O, Soylu A, Yaşar N, Demirbaş T, Dolapçıoğlu C et al. Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis? Diagn Interv Radiol. 2010 Dec;16(4):293-8. doi:10.4261/1305-3825.DIR.2989-09.1
  52. Jia Y, Li C, Yang X, Dong Z et al. CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis. BMC Gastroenterol. 2018 Nov 9;18(1):173. doi: 10.1186/s12876-018-0890-z
  53. Gashin L, Villafuerte-Galvez J, Leffler DA et al. Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis. 2015 Apr;21(4):793-800. doi: 10.1097/MIB.0000000000000321
  54. Милько В.И., Минцер О.П., Топчий Т.В., Корсуновский А.А. Клиническая оценка данных ирригоскопии при неспецифическом язвенном колите. Вест. Рентгенологии и радиологии. 1983; № 5, с. 46-50.
  55. Fraser GM, Findlay JM. The double contrast enema in ulcerative and Crohn"s colitis. Clin Radiol. 1976 Jan;27(1):103-12.
  56. Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., и соавт. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т.16, №6, с. 56-60.
  57. Peyrin-Biroulet L, Sandborn W, Sands B et al. Selecting Therapeutic Targets inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. https://doi.org/10.1038/ajg.2015.233
  58. Тurner D, Ricciuto A, Lewis A et al.; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090
  59. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; т.16, №3, с.58-62.
  60. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013; № 2, с.42-46.
  61. Reinisch W. Reinink A, Higgins P. Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2015;13:635-642.
  62. Dias CC, Rodrigues PP, da Costa-Pereira A et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156–63.
  63. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9(11):945-65.
  64. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и соавт. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. // Альманах клинической медицины. - 2020. - Т. 48. - №6. - C. 422-436. doi: 10.18786/2072-0505-2020-48-050
  65. Dinesen LC, Walsh AJ, Protic MN, Heap G et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431-437. https://doi.org/10.1016/j.crohns.2010.02.001
  66. Marshall JK, Thabane M, Steinhart AH, Newman JR et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 2010, Issue 1. Art. No.: CD004115. doi: 10.1002/14651858.CD004115
  67. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56:513–2256,57.
  68. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.
  69. Pokrotnieks J, Sitkin S. A proposed treatment algorithm for mild to moderate ulcerative colitis–with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018 Jun;53(6):799–800. doi: 10.1007/s00535-018-1458-y
  70. Regueiro M, Loftus Jr EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.
  71. Safdi M, DeMicco M, Sninsky C, Banks P et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.
  72. Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May 18;(5):CD000478. doi:10.1002/14651858.CD000478.pub4
  73. Ahmed I, Kassem W, Salam Y, Furnari M, Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J DigDis. 2018 Oct;10(4):220-229. doi: 10.15171/mejdd.2018.114
  74. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000543.
  75. Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.
  76. Ford AC, Khan KJ, Achkar JP et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. The American journal of gastroenterology. 2012;107:167-76.
  77. Nikfar S et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5- aminosalicylates in the induction of imp rovement and maintenance of remission in patients with ulcerative colitis. Digestive diseases and sciences. 2009;54(6):1157-1170.
  78. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3:210–8.
  79. Zhang Y, Chen D, Wang F, Li X, Xue X et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019 Mar;52(2):e12559. doi: 10.1111/cpr.12559. Epub 2019 Jan 18
  80. Danielsson A, Löfberg R, Persson T, Salde L et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992;27(1):9-12.
  81. Nguyen NH, Fumery M, Dulai PS, Prokop LJ et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi:10.1016/S2468-1253(18)30231-0
  82. D"Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44:1018-1029.
  83. Hartmann F1, Stein J; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010 Aug;32(3):368-76.
  84. Gross V1, Bar-Meir S, Lavy A, Mickisch O et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006 Jan 15;23(2):303-12.
  85. Matzen P. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol. 1991 Dec;26(12):1225-30.
  86. Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016 Feb;61(2):358-70.
  87. Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Oct 26;(10):CD007698.
  88. Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014 May;39(10):1095-103.
  89. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–37.
  90. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005;353:2462-2476.
  91. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65 e1-3.
  92. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-5.
  93. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369:699-710.
  94. Sandborn W SB, D"Haens GR et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology. 2016:S157
  95. Danese S, Vermeire S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5
  96. Sandborn W, Feagan BG et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617
  97. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3.
  98. Panaccione R, Ghosh S, Middleton S et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis. 2011;5:1376-1380. doi:10.1002/14651858.CD000478
  99. Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul;21(7):1709-18. 
  100. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015.
  101. Sandborn WJ, Su C, Sands BE et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.
  102. Reinisch W, Sandborn WJ, Rutgeerts P et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201–11.
  103. Danese S, D"Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018;24(10):2106-2112. doi:10.1093/ibd/izy076
  104. Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750
  105. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi:10.1111/apt.14422
  106. Shmidt E, Kochhar G, Hartke J et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory. Inflamm Bowel Dis. 2018;24(11):2461-2467. doi: 10.1093/ibd/izy171
  107. Sands BE, Armuzzi A, Marshall JK et al. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. J Crohns Colitis. 2018;12:49, https://doi.org/10.1093/ecco-jcc/jjx180.063.
  108. Turner D, Walsh CM, Steinhart AH et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-110.
  109. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-22.
  110. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227–32.
  111. Parlak E, Dağli U, Ulker A et al. Comparison of 5-aminosalicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol. 200;33(1):85-6.
  112. Khan KJ, Ullman TA, Ford AC, Abreu MT et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.
  113. Ohkusa T, Kato K, Terao S, Chiba T et al. Newly developed antibiotic combination therapy for ulcerativecolitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820–9.
  114. Sokol H, Seksik P, Carrat F, Nion-Larmurier I et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363–8.
  115. Chebli LA, Chaves LDdM, Pimentel FF, Guerra DM et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613–9.
  116. Ardizzone S, Maconi G, Russo A, Imbesi V et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.
  117. Халиф И.Л., Нанаева Б.А., Головенко А.О., Головенко О.В. Отдаленные результаты консервативного лечения больных с тяжелым обострением язвенного колита. Терапевтический архив. 2015;87(2):34-38. https://doi.org/10.17116/terarkh201587234-38.
  118. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.
  119. Lees CW, Heys D, Ho GT, Noble CL et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–9
  120. Van Assche G, D"Haens G, Noman M, Vermeire S et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.
  121. Sjoberg M, Walch A, Meshkat M, Gustavsson A et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18(2):212-8.
  122. Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013.5(23): 65-73.
  123. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut. 1975;16:579–84.
  124. Travis SP, Farrant JM, Ricketts C, Nolan DJ et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.
  125. Cima R. R. Timing and indications for colectomy in chronic ulcerative colitis: surgical consideration //Digestive diseases. – 2010. – Т. 28. – №. 3. – С. 501-507
  126. Provenzale D. et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis //Gastroenterology. – 1995. – Т. 109. – №. 4. – С. 1188-1196.
  127. Jess T, Loftus Jr EV, Velayos FS, Harmsen WS et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130:1039–46.
  128. Odze R. D. et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis //Clinical Gastroenterology and Hepatology. – 2004. – Т. 2. – №. 7. – С. 534-541.
  129. Fumery M. et al. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management //Journal of Crohn"s and Colitis. – 2021. – Т. 15. – №. 10. – С. 1766-1773.
  130. Feuerstein JD, Rakowsky S, Sattler L et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019; 90:186– 195.
  131. Iannone A, Ruospo M, Wong G et al. Chromoendoscopy for surveillance in ulcerative colitis and crohn’s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol 2017;15:1684–1697.
  132. Bessissow T, Dulai PS, Restellini S et al. Comparison of endoscopic dysplasia detection techniques in patients with ulcerative colitis: a systematic review and network meta-analysis. Inflamm Bowel Dis 2018;24:2518–2526.
  133. Alkandari A, Thayalasekaran S, Bhandari M et al. Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study. J Crohns Colitis. 2019; 28:13(11):1394-1400.
  134. Kinoshita S, Uraoka T, Nishizawa T et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. Gastrointest Endosc. 2018; 87(4):1079-1084.
  135. Andersen K, Vogt C, Blondin D et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur J Radiol. 2006;58:140–6.
  136. Richards DM, Hughes SA, Irving MH, Scott NA. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. 2001;3:223–6.
  137. McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis P et al. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis. 2009;15:1256–63.
  138. Marcello PW, Roberts PL, Schoetz Jr DJ, Coller JA et al. Long-term results of the ileoanal pouch procedure. Arch Surg. 1993;128:500–3 [discussion 503–4].    
  139. Sagar PM, Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis. 1997;15:172–88.      
  140. Meagher AP, Farouk R, Dozois RR, Kelly KA et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.
  141. Fleming FJ, Francone TD, Kim MJ, Gunzler D, Messing S, Monson JR. A laparoscopic approach does reduce short-term complications in patients undergoing ileal pouch-anal anastomosis. Dis Colon Rectum. 2011;54:176–82.
  142. Colombo F, Pellino G, Selvaggi F et al. Minimally invasive surgery and stoma-related complications after restorative proctocolectomy for ulcerative colitis. A two-centre comparison with open approach. Am J Surg. 2019;217:682–8.
  143. Ahmed  A, Keus  F, Heikens  J et  al. Open versus laparoscopic [assisted] ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009;1:CD006267.
  144. Tilney HS, Lovegrove RE, Heriot AG et al. Comparison of short-term outcomes of laparoscopic vs open approaches to ileal pouch surgery. Int J Colorectal Dis. 2007;22:531–42.
  145. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg. 2012;99:270–5.
  146. Sofo L, Caprino P, Sacchetti F, Bossola M. Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a narrative review. World J Gastrointest Surg. 2016;8:556–63.
  147. Setti-Carraro P, Ritchie JK, Wilkinson KH et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut. 1994;35:1070–1075.
  148. Fazio VW, Ziv Y, Church JM et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–127.
  149. Belliveau P, Trudel J, Vasilevsky CA et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg. 1999;42: 345–352.
  150. Pinto RA, Canedo J, Murad-Regadas S, Regadas SF et al. Ileal pouch-anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis. 2011;13:177–83.
  151. Church JM. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg. 2000;70:906–7.
  152. Chapman JR, Larson DW, Wolff BG, Dozois EJ et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005;140:534–40.
  153. Delaney CP, Dadvand B, Remzi FH et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum. 2002;45:890–4.
  154. Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg. 1999;86:493–5.
  155. Ording OK, Juul S, Berndtsson I, Oresland T et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002;122:15–9.
  156. Gorgun E, Remzi FH, Goldberg JM, Thornton J et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. 2004;136:795–803.
  157. Johnson P, Richard C, Ravid A, Spencer L et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2004;47:1119–26.
  158. Oresland T, Palmblad S, Ellstrom M, Berndtsson I et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis. 1994;9:77–81.
  159. Alves A, Panis Y, Bouhnik Y, Maylin V et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379–85
  160. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45–51.
  161. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48: 70–3.
  162. Holubar SD, Larson DW, Dozois EJ, Pattana-Arun J et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum. 2009;52:187–92.
  163. Marceau C, Alves A, Ouaissi M, Bouhnik Y et al. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery. 2007;141:640.
  164. Annibali R, Oresland T, Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum. 1994;37:321–9.
  165. Burns EM, Bottle A, Aylin P, Clark SK et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg. 2011;98:408–17.
  166. Tekkis PP, Fazio VW, Lavery IC, Remzi FH et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg. 2005;241:262–8.
  167. Lepisto A. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg. 2005;94:40–2.
  168. Edwards, C.M., George B, Warren F. Diversion colitis: new light through old windows. Histopathology. 1999.35(1):86-7.
  169. Shepherd NA, Jass JR, Duval I, Moskowitz RL et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601–7.
  170. SettiCarraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis. 1998;13:103–7.
  171. Ferrante M, D"Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062–70.
  172. Lake JP, Firoozmand E, Kang JC, Vassiliu P et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004;8:547–51.
  173. Mahadevan U, Loftus Jr EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8:311–6.
  174. Pugliese D, Armuzzi A, Rizzo G et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. 2010;59(Suppl III):A13.
  175. Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006;93:793–9.
  176. Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012 Nov;36(10):922-8. doi: 10.1111/apt.12060. Epub 2012 Sep 24
  177. Meagher AP, Farouk R, Dozois RR, Kelly KA et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.
  178. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851–6.
  179. Stahlberg D, Gullberg K, Liljeqvist L, Hellers G et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012–8.
  180. Penna C, Tiret E, Kartheuser A, Hannoun L et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg. 1993;80:765–7.
  181. Tjandra JJ, Fazio VW, Church JM, Oakley JR et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993;165:322–5.
  182. Poo S., Sriranganathan D., Segal J. P. Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis //European Journal of Gastroenterology & Hepatology. – 2022. – Т. 34. – №. 5. – С. 518-528
  183. Viazis N, Giakoumis M, Koukouratos T et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis, Journal of Crohn"s and Colitis. 2013;7(10):457–460.
  184. Travis S, Silverberg MS, Danese S et al. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. Journal Crohns Colitis. 2022;16(Supplement_1):i004–5
  185. Peter J, Zeitz J, Stallmach A. Ustekinumab Rescue Therapy in a Patient With Chronic Refractory Pouchitis. Journal of Crohn"s and Colitis. 2018;12(8):1008–1009.
  186. Сухина М.А., Образцов И.В., Михалевская В.И., Ачкасов С.И., Сафин А.Л., Шелыгин Ю.А. Алгоритм лабораторной диагностики clostridium difficile-ассоциированной диареи. Журнал микробиологии, эпидемиологии и иммунобиологии (ЖМЭИ). 2018;(2):45-53.
  187. Шелыгин Ю.А., Алёшкин В.А., Сухина М.А., Миронов А.Ю., и др. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи, и общероссийской общественной некоммерческой организации «Ассоциация колопроктологов России» по диагностике, лечению и профилактике Сlostridium difficile-ассоциированной диареи (cdi). Колопроктология. 2018;(3):7-23. https://doi.org/10.33878/2073-7556-2018-0-3-7-23.
  188. Aguado JM, Anttila VJ, Galperine T, Goldenberg SD et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J Hosp Infect. 2015;2(50):117-125.
  189. Metan G, Türe Z, Kaynar L. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy. 2015;6(27):354–357.
  190. Chiu CY, Sarwal A, Feinstein A, Hennessey K. Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2019 Oct 1;8(4). pii: E173. doi: 10.3390/antibiotics8040173.
  191. Tschudin-Sutter S, Braissant O, Erb S et al. Growth Patterns of Clostridium difficile – Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One. 2016;9(11):e0161711.
  192. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; №5, с.77-83.
  193. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015; №5-6, с.16-20.
  194. Rahier JF, Magro F, Abreu C, Armuzzi A et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCrohns Colitis. 2014 Jun;8(6):443-68. doi: 10.1016/j.crohns.2013.12.013. Epub 2014 Mar 6
  195. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005.172(9):1169-227.
  196. Franchimont D, Ferrante M, Louis E et al. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD); Acta Gastroenterol Belq 2018;81:49–53.
  197. Lin WC, Chang CW, Chen MJ, Hsu TC, Wang HY. Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. Medicine (Baltimore). 2019 May;98(21):e15748. doi: 10.1097/MD.0000000000015748
  198. Colombel JF, Ordás I, Ullman T, Rutgeerts P et al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):389-95.e3. doi: 10.1053/j.gastro.2015.10.016
  199. Annese V., Daperno M., Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018.
  200. Puolanne AM, Kolho KL, Alfthan H, Färkkilä M. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. Scand J Gastroenterol. 2019 Jul;54(7):849-854. doi: 10.1080/00365521.2019.1618910
  201. Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019 Jun;15(6):667-677. doi: 10.1080/1744666X.2019.1593140
  202. Князев О.В., Каграманова А.В., Корнеева И.А. и соавт. Значение фекального кальпротектина в мониторинге активности воспалительных заболеваний кишечника. Терапевтический архив. 2019; 91 (4): 53–61. DOI: 10.26442/00403660.2019.04.000229
  203. Trigo-Vicente С., Gimeno-Ballester V et al. Systematic review and network meta‑analysis of treatmentfor moderate‑to‑severe ulcerative colitis. Int J Clin Pharm. 2018 Dec;40(6):1411-1419. doi: 10.1007/s11096-018-0743-4
  204. Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835-848.
  205. Olivera P., Zuily S. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857-873. doi: 10.1038/s41575-021-00492-8
  206. Подольская Д.В., Шапина М.В., Баранова Т.А., Тишаева И.А., Александров Т.Л., Князев О.В., Нанаева Б.А.  Эффективность тофацитиниба в качестве «терапии спасения» у пациентов с язвенным колитом тяжелой степени.  Колопроктология. 2021;20(3):43–50. https://doi.org/10.33878/2073-7556-2021-20-3-43-50
  207. Kotwani P., Terdiman J, Lewin S. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. J CrohnsColitis. 2020 Jul 30;14(7):1026-1028. doi: 10.1093/ecco-jcc/jjaa018
  208. Xiao Y, Benoit N, Sedano R. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Dig Dis Sci. 2022. doi: 10.1007/s10620-022-07439-2
  209. Goetgebuer L et al. Kreijne Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. Journal of Crohn"s and Colitis. 2021, 1464–1473. doi:10.1093/ecco-jcc/jjab036
  210. Sands B, Peyrin-Biroulet L, Loftus E et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725
  211. Bressler B, Yarur A, Silverberg M et al. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058
  212. Bressler B, Yarur A, Kopylov U et al. Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn’s Disease. United European Gastroenterol J. 2019;7(8(Supplement)). Poster P1091.
  213. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMA/CHMP/BWP/247713/2012. Available at: https://www.ema.europa.eu/en/ documents/scientific-guideline/ guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Last accessed: September 2022.
  214. IQVIA. The impact of biosimilar competition in Europe. 2021. Available at: https://www.iqvia. com/-/media/iqvia/pdfs/library/ white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf. Last accessed: 17 October 2022.
  215. Humphry N. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance. EMJ Gastroenterol. 2022;11[Suppl 7]:2-10. https://doi.org/10.33590/emjgastroenterol/10106137.
  216. Danese S, Fiorino G, Raine T et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11:26-34.
  217. Cohen H, Blauvelt A, Rifkin RM et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463-78.
  218. Massimi D, Barberio B, Bertani L et al. Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study. Ther Adv Gastroenterol. 2021;14:1-11.
  219. Trystram N, Abitbol V, Tannoury J et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 inpatients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53:887-99.
  220. Mahmmod S, Schultheiss JPD, van Bodegraven AA et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1954- 62.
  221. Kaniewska M, Rosolowski M, Moniuzsko A et al. Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients. Prz Gastroenterol. 2021;16:207-12.
  222. Morris GA, McNikol M, Boyle B et al. Increasing biosimilar utilization at a pediatric inflammatory bowel disease center and associated cost savings: show me the money. Inflamm Bowel Dis. 2022;28:531-8.
  223. Barberio B. Cingolani L, Canova C et al. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Ther Adv Gastroenterol. 2021;14:175-82.
  224. Kurki P, Barry S., Bourges I et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881-96.
  225. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn"s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.
  226. Cordón JP, Arranz EM, Ramírez L, Arranz M. What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF? A. Cerpa Arencibia, C. Suarez Ferrer. Journal of Crohn s and Colitis. January 2020; 14 (Supplement_1):S554-S554.
  227. Stavem K. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. J Mark Access Health Policy. 2021; 9(1):1964792. Published online 2021 Aug 20. DOI: 10.1080/20016689.2021.1964792 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381978/
  228. Князев О.В., Звяглова М.Ю., Каграманова А.В. и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021; 93 (2): 150–157. DOI: 10.26442/00403660.2021.02.200624.
  229. Gisbert J. P. et al. Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis //Alimentary pharmacology & therapeutics. – 2009. – Т. 30. – №. 2. – С. 126-137.
  230. Sood A. et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial //Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology. – 2000. – Т. 19. – №. 1. – С. 14-16.
  231. Kuriyama M. et al. Tolerability and usefulness of mercaptopurine in azathioprine‐intolerant Japanese patients with ulcerative colitis //Digestive Endoscopy. – 2010. – Т. 22. – №. 4. – С. 289-296
  232. Meier J., Sturm A. Current treatment of ulcerative colitis //World journal of gastroenterology: WJG. – 2011. – Т. 17. – №. 27. – С. 3204.
  233. Ng S. C., Kamm M. A. Therapeutic strategies for the management of ulcerative colitis //Inflammatory bowel diseases. – 2009. – Т. 15. – №. 6. – С. 935-950
  234. Абдулхаков С. Р., Абдулхаков Р. А. Неспецифический язвенный колит: современные подходы к диагностике и лечению //Вестник современной клинической медицины. – 2009. – Т. 2. – №. 1. – С. 32-41.
  235. O. Petitjean, J. L. Wendling, M. Tod, et all/ Pharrnacokinetics and absolute rectal bioavaila bility of hydrocortisone acetate in distal colitis // Aliment. Pharmacol. Ther. (1992) 6, 35 1-357.
  236. Lloyd R. Sutherland. Topical Treatment of  Ulcerative Colitis// Medical Clinics of North America-Vol.74, No. 1, January 1990
  237. Pleet J. L. et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis //Alimentary pharmacology & therapeutics. – 2014. – Т. 39. – №. 9. – С. 940-948
  238. Sands B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis //New England Journal of Medicine. – 2019. – Т. 381. – №. 13. – С. 1201-1214.
  239. Sandborn W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis //New England Journal of Medicine. – 2017. – Т. 376. – №. 18. – С. 1723-1736.
  240. Gies N. et al. Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort //Alimentary pharmacology & therapeutics. – 2010. – Т. 32. – №. 4. – С. 522-528.
  241. Gemayel N. C. et al. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence //Current Medical Research and Opinion. – 2019. – Т. 35. – №. 11. – С. 1911-1923.
  242. Burr N. E. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis //Gut. – 2022. – Т. 71. – №. 10. – С. 1976-1987.
  243. Travis S. P. L. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study //Gut. – 2014. – Т. 63. – №. 3. – С. 433-441.
  244. Panaccione R. et al. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review //Advances in Therapy. – 2023. – Т. 40. – №. 5. – С. 2051-2081.
  245. Sofia M. A., Rubin D. T. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis //Therapeutic advances in gastroenterology. – 2016. – Т. 9. – №. 4. – С. 548-559.
  246. Ferretti F. et al. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis //Journal of Clinical Medicine. – 2022. – Т. 11. – №. 9. – С. 2302\
  247. Pleet J. L. et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis //Alimentary pharmacology & therapeutics. – 2014. – Т. 39. – №. 9. – С. 940-948
  248. Christophorou D. et al. Systematic review with meta‐analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis //Alimentary Pharmacology & Therapeutics. – 2015. – Т. 41. – №. 7. – С. 603-612
  249. Woolrich A. J., DaSilva M. D., Korelitz B. I. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia //Gastroenterology. – 1992. – Т. 103. – №. 2. – С. 431-438.
  250. Gionchetti P. et al. Oral budesonide in the treatment of chronic refractory pouchitis //Alimentary pharmacology & therapeutics. – 2007. – Т. 25. – №. 10. – С. 1231-1236.
  251. Segal J. P. et al. Systematic review with meta‐analysis: the management of chronic refractory pouchitis with an evidence‐based treatment algorithm //Alimentary Pharmacology & Therapeutics. – 2017. – Т. 45. – №. 5. – С. 581-592.
  252. Khoo E. et al. Systematic Review and Meta-analysis of Immunomodulator and Biologic Therapies for Treatment of Chronic Pouchitis //medRxiv. – 2021. – С. 2021.01. 19.21250059
  253. Rao K., Higgins P. D. R. Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease //Inflammatory bowel diseases. – 2016. – Т. 22. – №. 7. – С. 1744-1754.
  254. Silva J. et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin //The American Journal of Medicine. – 1981. – Т. 71. – №. 5. – С. 815-822.
  255. Nitzan O. et al. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment //World journal of gastroenterology: WJG. – 2013. – Т. 19. – №. 43. – С. 7577.
  256. Bamba S. et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis //Journal of gastroenterology and hepatology. – 2010. – Т. 25. – №. 3. – С. 494-498.
  257. Papa A, Gerardi V, Marzo M, Felice C, Rapaccini GL, Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol. 2014 Mar 28;20(12):3173-9. doi: 10.3748/wjg.v20.i12.3173.
  258. Tinsley A, Naymagon S, Enomoto LM, Hollenbeak CS, Sands BE, Ullman TA. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis. 2013 Dec;7(12):e635-40. doi: 10.1016/j.crohns.2013.05.002
  259. Lightner AL, Sklow B, Click B, Regueiro M, McMichael JJ, Jia X, Vaidya P, Delaney CP, Cohen B, Wexner SD, Steele SR, Holubar SD. Venous Thromboembolism in Patients Admitted for IBD: An Enterprise-Wide Experience of 86,000 Hospital Encounters. Dis Colon Rectum. 2023 Mar 1;66(3):410-418. doi: 10.1097/DCR.0000000000002338
  260. Hiroshi N., (2022). Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut and Liver. 17. 10.5009/gnl220017.
  261. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 Apr;158(5):1465-1496.e17. doi: 10.1053/j.gastro.2020.01.007. Epub 2020 Jan 13. PMID: 31945351; PMCID: PMC7117094.
  262. Wenjie Xi , Zongwei Li , Rongrong Ren , Xiao-Yong Sai , Lihua Peng &Yunsheng Yang (2020): Effect of antibiotic therapy in patients with ulcerative colitis: a metaanalysis of randomized controlled trials, Scandinavian Journal of Gastroenterology, DOI:10.1080/00365521.2020.1858958
  263. Sehgal P. et al. Systematic review: safety of mesalazine in ulcerative colitis //Alimentary pharmacology & therapeutics. – 2018. – Т. 47. – №. 12. – С. 1597-1609.
  264. Sandborn W. J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis //Gastroenterology. – 2020. – Т. 158. – №. 8. – С. 2139-2149. e14. – 2В
  265. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800. doi: 10.1056/NEJM199909093411103. PMID: 10477777.
  266. Gionchetti P. et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis //Alimentary pharmacology & therapeutics. – 1997. – Т. 11. – №. 6. – С. 1053-1057.
  267. Д. Д. Тарасова, Л. Н. Шилова, М. В. Королeва, Современные аспекты терапии язвенного колита №2 2019 (74) - "Актуальные вопросы фармакотерапии в гастроэнтерологии. Стр. 28-32
  268. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997 Jun;40(6):775-81. doi: 10.1136/gut.40.6.775. PMID: 9245932; PMCID: PMC1027203.
  269. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone. Br Med J. 1956 Dec 1;2(5004):1267-72. doi: 10.1136/bmj.2.5004.1267. PMID: 13374319; PMCID: PMC2036121.
  270. Turunen UM, Färkkilä MA, Hakala K, Seppälä K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998 Nov;115(5):1072-8. doi: 10.1016/s0016-5085(98)70076-9. PMID: 9797360.
  271. Rutter M. D. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis //Gastroenterology. – 2006. – Т. 130. – №. 4. – С. 1030-1038.
  272. Hata K. et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population //British journal of cancer. – 2003. – Т. 89. – №. 7. – С. 1232-1236.
  273. Taylor K., Gibson P. R. Conventional therapy of ulcerative colitis: corticosteroids //Crohn"s Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. – 2017. – С. 399-412.
  274. Clore J. N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia //Endocrine practice. – 2009. – Т. 15. – №. 5. – С. 469-474.
  275. Shaye O. A. et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients //Official journal of the American College of Gastroenterology| ACG. – 2007. – Т. 102. – №. 11. – С. 2488-2494

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*